plenary Flashcards

1
Q

limitations of mammogram

A
  • subjective
  • lack of consistency in positioning
  • missing cancers in periphery if exposure not adequate
  • dense breast
  • can be uncomfortable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

multi disciplinary team

A

Improves communication, coordination and decision making

Improved care

Up to date with evidence based practice

Breast Surgeons/Oncologists/Pathologist/Radiologists/Cancer Nurse Specialists/Mammographers/Plastic Surgeons/MDT coordinator/Research Nurses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

breaking bad news

A

Setting
Quiet room/Adequate privacy
Involve your Cancer Nurse Specialist
Avoid distractions: pagers/ Phones

Assess patients perception
Before you tell, ask

Warning shots may lessen the shock

Address patients emotions with empathy
Silence to disbelief, crying, denial or anger

  • offer contact number
  • offer follow up consultation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

surgery

A

Breast Conservation Surgery
Wide Local Excison
Oncoplastic Procedures

Mastectomy

Reconstruction
Immediate or delayed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

magseed marked wide local excision

A
Stainless stell Pellet
5x1mm
Seed is not magnetic
Temporarily magnetised by Sentimag Probe
18 Gauge Deployment
USS visible
Can be placed under US/Mammo/Tomo guidance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

staging TNM

A

Early Stage ( Cancer not beyond breast and regional LNs)
Stage 0
DCIS
Stage 1

Stage 2

Locally Advanced Breast Cancer
Stage 3
Inflammatory Breast Cancer

Advanced Breast Cancer
Stage 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

5 year survival

A

Stage 1

98%

Stage 2

90%

Stage 3

70%

Stage 4

25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

endocrine treatment

A
Oestrogen receptor
SERM ( Selective Estrogen Receptor Modulator)
Tamoxifen,Raloxifene
Aromatase inhibitors
Letrozole,Anastrozole,Exemestane
Second line endocrine Treatment
Everolimus
PI3K/AKTmTOR pathway down regulator
Palbociclib,ribociclib 
CDK4/6 inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

anti her 2 treatment

A

Her 2 marker
20-25% breast cancer shows Her 2 protein overexpression

Trastuzumab

Pertuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

neoadjuvant therapy

A

NACT ( Neoadj Chemotherapy)

NAET ( Neoadj Endocrine Therapy)

Rarely RT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

metastatic cancer

A

Symptom directed investigation and treatment

Mostly palliative treatment

Longer survival in oligometastatic disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly